Eastern Time (US & Canada) July 19, 2019, CASI Pharmaceuticals, Inc. (Nasdaq: CASI) entered into an Open Market Sale AgreementSM with Jefferies LLC. Pursuant to the terms of the Sales Agreement, CASI may elect to sell from time to time, at its option, up to $30 million shares of its common stock through Jefferies LLC, as sales agent by any method permitted that is deemed an 'at the market offering' as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.
Guantao team led by Hong Kong office managing partner Grace Pengpeng YAN and Yan RONG acted as the legal adviser to Jefferies LLC as to the laws of the People’s Republic of China.
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and high quality pharmaceutical products in China, U.S., and throughout the world.